By Don Nico Forbes


Shares in GT Biopharma rose 15% after receiving approval from the U.S. Food and Drug Administration to begin Phase 1 trials for its GTB-3650 treatment for leukemia.

Trials are expected to start in second half of 2024, with initial clinical data expected to follow in the first half of 2025, the biopharmaceutical company said Thursday.

"GTB-3650 is designed to target [natural killer] cells within the immune system to potentially overcome many of the limitations of current [acute myeloid leukemia] chemotherapies... our trial design should give us an early read on safety and potential therapeutic activity," Chief Executive Michael Breen said.


Write to Don Nico Forbes at don.forbes@wsj.com


(END) Dow Jones Newswires

06-27-24 1005ET